Vaxfab Enterprises Posts Standalone Profit Amid Auditor's Disclaimer of Opinion

For the financial year ended March 31, 2026, Vaxfab Enterprises reported standalone revenue of ₹94.11 crore and a standalone profit of ₹3.64 crore.
Consolidated revenue stood at ₹131.26 crore, but the company reported a consolidated loss of ₹-4.63 crore.

Reader Takeaway: Standalone profit is overshadowed by auditor's disclaimer and consolidated loss, signaling governance risks.

What just happened

Vaxfab Enterprises Limited announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a standalone profit of ₹3.64 crore on revenues of ₹94.11 crore. However, on a consolidated basis, Vaxfab registered a loss of ₹4.63 crore on revenues of ₹131.26 crore.

A significant development is that the statutory auditor, Chandabhoy & Jassoobhoy, has issued a Disclaimer of Opinion on both the standalone and consolidated financial statements. This means the auditor could not obtain sufficient audit evidence to express an opinion on the fairness of the financial statements.

Why this matters

The auditor's disclaimer is a major red flag for investors. It indicates serious deficiencies in the company's accounting records and internal controls. The auditor cited inadequate maintenance of records by previous management, issues with unsecured loans granted and received without formal agreements, and non-compliance with the MSMED Act.

Furthermore, the consolidated results included unaudited financial information from a subsidiary and an LLP, provided solely by management. This divergence between standalone profit and consolidated loss, coupled with the disclaimer, raises significant doubts about the reliability of Vaxfab's financial reporting.

The backstory

Vaxfab Enterprises operates in the single segment of Trading of Goods. The auditor's report highlights that records pertaining to prior periods were not adequately maintained by previous management, affecting sales, purchases, inventory, receivables, and payables. The company also dealt with unsecured loans without proper documentation and failed to classify creditors under the MSMED Act.

What changes now

Investors need to approach Vaxfab Enterprises' financial performance with extreme caution. The disclaimer of opinion suggests that the financial health and operational transparency of the company are uncertain. Shareholders should closely monitor how the company addresses the auditor's concerns regarding record-keeping and governance.

Risks to watch

The primary risks stem from the auditor's disclaimer, pointing to potential weaknesses in corporate governance and financial transparency. The reliance on unaudited data for consolidated results and issues surrounding unsecured loans also present significant financial and operational risks.

Context metrics

As at March 31, 2026, Vaxfab Enterprises reported standalone equity of ₹48.06 crore and consolidated equity of ₹43.52 crore.

What to track next

Investors should look for updates on how Vaxfab Enterprises plans to rectify the record-keeping deficiencies and improve its internal controls and compliance. Any further clarifications from the auditor or management regarding the disclaimer of opinion will be crucial.